<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48492">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01780428</url>
  </required_header>
  <id_info>
    <org_study_id>CLCT-002</org_study_id>
    <nct_id>NCT01780428</nct_id>
  </id_info>
  <brief_title>Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Multiple-dose Multi-Center Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charleston Laboratories, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charleston Laboratories, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, multiple-dose, placebo- and positive-controlled study of
      CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) in patients with moderate to
      severs pain following surgical removal of impacted third molar teeth.

      A positive control ( Norco, A commercial formulation of hydrocodone 7.5 mg/APAP 325 mg) is
      included to determine the anti-emetic effects of CL-108.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>To compare the occurrence and severity of opioid-induced nausea and vomiting (OINV) associated with CL-108 to Norco.</measure>
    <time_frame>Over the first 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>After data has been locked.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To demonstrate the efficacy of CL-108 when compared to placebo for the relief of pain following surgical removal of impacted third molar teeth.</measure>
    <time_frame>over 24 hours (SPID24)</time_frame>
    <safety_issue>No</safety_issue>
    <description>After data has been locked.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of the severity of nausea in patients treated with an opioid-containing pain reliever.</measure>
    <time_frame>over 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>After data lock.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of vomiting in patients treated with an opioid-containing pain reliever.</measure>
    <time_frame>over 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>After data lock.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Elimination of vomiting in patients treated with an opioid-containing pain reliever.</measure>
    <time_frame>6 hours and 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>After data lock.</description>
  </other_outcome>
  <other_outcome>
    <measure>Elimination of nausea in patients treated with an opioid-containing pain reliever.</measure>
    <time_frame>6 hours and 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>After data lock.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">810</enrollment>
  <condition>Pain</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>CL-108</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CL-108 hydrocodone 7.5 mg,APAP 325 mg, Promethazine 12.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norco</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercial product containing hydrocodone 7.5 mg. APAP 325 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CL-108 formulation without API</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CL-108</intervention_name>
    <arm_group_label>CL-108</arm_group_label>
    <arm_group_label>Norco</arm_group_label>
    <other_name>Norco</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Determination of being likely or possibly nausea-prone.

          -  Male or non-pregnant and non-lactating female.

          -  Surgical extraction of at least 2 impacted third molar teeth

          -  A female of child-bearing potential is eligible to participate in this study if  she
             has a negative urine pregnancy test and is using an acceptable method of birth
             control.

          -  Surgical extraction of  at least 2 impacted third molar teeth.

          -  Presence of at least moderate post-operative pain.

        Exclusion Criteria:

          -  Medial Condition, presence of a serious medical condition.

          -  Active local infection.

          -  Drug Allergy history of hypersensitivity to an Opioid, Promethazine, Acetaminophen.

          -  Caffeine use since midnight before the operation.

          -  Use of an IND Drug within past 30 days.

          -  Previous participation in this study.

          -  Pregnant or lactating.

          -  Employee of the PI,sub-investigator or Charleston Labs or relative of an employee.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benard P Schachtel, M.D.</last_name>
    <phone>5615757330</phone>
    <email>bschachlet@charlestonlabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-6030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey A Secreto, Med. Tech.</last_name>
      <phone>215-746-8871</phone>
    </contact>
    <investigator>
      <last_name>Elliot V HErsh, D.M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.charlestonlabs.com</url>
    <description>Charleston Website</description>
  </link>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 30, 2013</lastchanged_date>
  <firstreceived_date>January 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charleston Laboratories, Inc</investigator_affiliation>
    <investigator_full_name>John Ameling</investigator_full_name>
    <investigator_title>Vice-President</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
